Artificial Intelligence in Drug Development
LiVeritas Biosciences, Inc. has announced the beta testing of their LiLii™ platform, a cutting-edge, fully integrated laboratory ecosystem that leverages proprietary LiVeritas® AI (artificial intelligence) to simplify workflows, enhance efficiency, and optimize productivity for drug developers across all stages of development.
The LiLii™ platform operates as a Software as a Service (SaaS) for analytical laboratory operations and project management. It combines analytical tools with an AI
biopharma knowledge base, empowering drug developers of all sizes with seamless data processing, analysis, and reporting through a single intuitive interface.
By eliminating the need for multiple software packages, the LiLii platform promises to significantly accelerate drug development by generating high-quality data and analytics at a faster pace.
On the operational side, the LiLii platform integrates project management, customer relationship management (CRM), document management, and communications capabilities.
The translation of sample information into scientifically useful data is instantaneous, reducing the time required for project initiation and setup while minimizing the risk of errors that can occur during the manual onboarding of client and lab-generated information.
Through the LiLii platform, drug developers can process sample data at least 15 times faster with improved data integrity compared to traditional manual methods that rely on fragmented tools and isolated workflows. This leads to more cost-efficient outcomes with reduced risk.
Dr. Nina Cortina, Co-Founder and VP Technology Development at LiVeritas, explains, "The LiLii platform centralizes communications under a single point of digital interaction, eliminating the need for clients to communicate through multiple separate channels.
Our platform serves as an information aggregator, ensuring consistency and transparency between the client and LiVeritas. This enables our team to carry out analytical services more rapidly, efficiently, and effectively."
In addition to enhancing internal testing operations for biopharma, the LiLii platform can be integrated into any analytical testing laboratory, regardless of the industry. Its AI capabilities enhance end-users' analytical skills, which are in high demand but increasingly scarce.
Lieza Danan, Ph.D., Co-Founder and CEO of LiVeritas Biosciences, states, "The LiLii platform is the culmination of a holistic vision that developed while I led mass spectrometry and analytical development functions in biopharma. Instead of relying on fragmented tools of the past, I needed optimized, automated workflows to address the urgent needs of various drug development functions.
With our founding team's diverse backgrounds in chemistry, computer engineering, and over 100 years of analytical testing experience, we have created a scalable, tech-enabled platform that empowers end-users to rapidly generate consistent, high-quality data for actionable insights, unlocking value in Biopharma Industry 4.0 and beyond."
The LiLii platform's architecture is designed to be modular and expandable, allowing for seamless interfacing with existing ERP (Enterprise Resource Planning) systems to support a business's strategy directly.
Source
